Skip to main content

Eliminating the Public Health Problem of Hepatitis B and C in the United States Phase One Report (2016) / Chapter Skim
Currently Skimming:

Appendix B: Committee Meeting 2 Agenda
Pages 143-146

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 143...
... B Committee Meeting 2 Agenda COMMITTEE ON A NATIONAL STRATEGY FOR THE ELIMINATION OF HEPATITIS B AND C The Keck Center, 500 Fifth Street NW Washington, DC 20001 December 16, 2015 Room 105 THE SCIENTIFIC AND CLINICAL FEASIBILITY OF ELIMINATING HCV 8:45-9:00 Welcome and Introductions Brian Strom, Committee Chair 9:00-9:30 The Epidemiology and Natural History of Hepatitis C Virus David Thomas, Professor of Medicine and Director of Infectious Diseases, Johns Hopkins University School of Medicine 9:30-10:00 Screening and Clinical Management of Hepatitis C Marc Ghany, Staff Clinician, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health 143
Read the entire page →
From page 144...
... 144 ELIMINATING HEPATITIS B AND C IN THE UNITED STATES 10:00-10:30 Treatment of Hepatitis C Jay Hoofnagle, Director, Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health 10:30-10:45 Break 10:45-11:15 Prevalence of HCV and a Framework for Understanding Cost-Effectiveness Arthur Kim, Director Viral Hepatitis Clinic, Massachusetts General Hospital 11:15-12:30 Panel Discussion on the Scientific and Clinical Feasibility of Eliminating HCV Stuart Ray, Moderator •  avid Thomas, Professor of Medicine and Director of D Infectious Diseases, Johns Hopkins University School of Medicine •  arc Ghany, Staff Clinician, Liver Diseases Branch, M National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health •  ay Hoofnagle, Deputy Director, Liver Disease J Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health •  rthur Kim, Director Viral Hepatitis Clinic, A Massachusetts General Hospital THE LOGISTICAL AND SOCIAL FEASIBILITY OF ELIMINATING HCV 1:30-2:00 Price and Access to Hepatitis C Drugs Camilla Graham, Assistant Professor of Medicine, Beth Israel Deaconess Medical Center 2:00-2:30 The National Infrastructure for Hepatitis C: Is There Anyone Home? Daniel O'Connell, Director, New York State Department of Health AIDS Institute 2:30-2:45 Break
Read the entire page →
From page 145...
... APPENDIX B 145 2:45-3:15 The Feasibility of Eliminating Hepatitis C Among Injection Drug Users Brian Edlin, Senior Principal Investigator, Institute for Infectious Disease Research National Development and Research Institutes 3:15-3:45 The Logistics of Reaching the Hepatitis C Patient in Corrections Lara Strick, Infectious Disease Specialist, Washington State Department of Corrections (by video) 3:45-5:00 Panel Discussion on the Logistical and Social Feasibility of Eliminating HCV Paul Kuehnert, Moderator •  amilla Graham, Assistant Professor of Medicine, C Beth Israel Deaconess Medical Center •  rian Edlin, Senior Principal Investigator, Institute for B Infectious Disease Research National Development and Research Institutes •  aniel O'Connell, Director, New York State D Department of Health AIDS Institute
Read the entire page →

Key Terms



This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.